StockData

Alector vs Regenxbio

ALEC and RGNX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ALEC and RGNX compare

Regenxbio is the larger company, worth 1.7 times as much as Alector ($478M against $286M).

Regenxbio grew revenue faster over the last twelve months (12.0% versus −82.9% for Alector).

Regenxbio keeps more of each dollar of sales as profit, with a net margin of −113% compared with −850% at Alector.

Regenxbio scores higher on the StockData Score (4 against 1 for Alector), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricALECRGNX
Size and price
Market cap$286M$478M
Share price$2.56$7.24
Change, 1 year106%−37.1%
Change, 5 years−87.1%−76.6%
Beta (5Y)1.912.63
Employees103371
StockData Score
Total score14 (better)
Valuation score00
Growth score02 (better)
Performance score01 (better)
Health score11
Dividend score00
Valuation
P/S20.6×2.7× (better)
P/B–6.7×
FCF yield−55.4%−52.2% (better)
Growth
Revenue growth (TTM)−82.9%12.0% (better)
Revenue growth, 5Y average−0.05%2.0% (better)
Profitability
Operating margin−912%−94.1% (better)
Net margin−850%−113% (better)
FCF margin−1143%−143% (better)
Return on equity−385%−138% (better)
Financial health
Interest coverage–−3.9×
Current ratio5.26 (better)2.86
Altman Z-score−7.35−3.88 (better)
Piotroski F-score14 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions85.8%64.2%
Held by insiders9.6%7.6%
Insider net buying, 12 months−$1.0M$9.6K (better)
Short interest, % of float8.3%16.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.